FENC
Fennec Pharmaceuticals Inc.
FENC's fundamentals are strong: revenue grew 71% and its operating margin went from −12% to 5.6%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
FENC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Unavailable |
FENC's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
FENC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $10.90 | — |
| Current | 1,090x | $10.90 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
FENC's PE is 1090x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
FENC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
FENC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
FENC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.68 | +6660% |
| Q3 2026 | $0.01 | +$0.25 |
| Q2 2026 | -$0.13 | +$0.30 |
| Q1 2026 | -$0.29 | +$0.23 |
| Q4 2025 | -$0.34 | -$0.27 |
| Q3 2025 | -$0.24 | +$0.83 |
| Q2 2025 | -$0.43 | +$0.50 |
| Q1 2025 | -$0.52 | +$0.42 |
| Q4 2024 | -$0.07 | +$1.51 |
FENC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
FENC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.6M | +57% |
| Q2 2026 | $17.9M | +85% |
| Q1 2026 | $15.1M | +73% |
| Q4 2025 | $13.8M | +74% |
| Q3 2025 | $12.5M | +79% |
| Q2 2025 | $9.7M | +33% |
| Q1 2025 | $8.8M | -66% |
| Q4 2024 | $7.9M | -20% |
FENC's revenue is recovering but still below its 2024 peak: $20M last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +25 points |
| Q2 2026 | 9.7% | +38 points |
| Q1 2026 | -0.8% | +8.4 points |
| Q4 2025 | -19% | -6.8 points |
| Q3 2025 | -1.5% | +73 points |
| Q2 2025 | -28% | +41 points |
| Q1 2025 | -9.2% | -63 points |
| Q4 2024 | -12% | +6.5 points |
FENC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
FENC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +348% |
| Q2 2026 | $50K | +$3.7M |
| Q1 2026 | $2.4M | +$6.7M |
| Q4 2025 | -$6M | -$4.5M |
| Q3 2025 | $1.5M | +$3.7M |
| Q2 2025 | -$3.7M | +$4.7M |
| Q1 2025 | -$4.3M | -111% |
| Q4 2024 | -$1.5M | +$3.4M |
FENC's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over FENC on cash flow, with more consistent year-over-year improvement.
FENC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.5% | +1.6M shares |
| 1 year | +37% | +10.2M shares |
| 3 years | +43% | +11.5M shares |
| 5 years | +46% | +12.1M shares |
| Available history | +91% | +18.2M shares |
FENC has 38M diluted shares, up 37% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over FENC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
FENC Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
FENC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.6 | Neutral |
| Stochastic | 26.3 | Neutral |
FENC's weekly RSI is 56 (neutral) and its Stochastic is 26 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
FENC PE vs Healthcare Sector
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
FENC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 5.6% above |
| 20 week MA | $10.7 | 1.6% above |
| 50 week MA | $9.05 | 20% above |
| 100 week MA | $8.25 | 32% above |
| 200 week MA | $8.06 | 35% above |
FENC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
FENC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.23 | $7.16 | +15% |
| 2021 | $7.16 | $4.49 | -37% |
| 2022 | $4.49 | $9.78 | +118% |
| 2023 | $9.78 | $11.2 | +15% |
| 2024 | $11.2 | $6.22 | -45% |
| 2025 | $6.22 | $8.09 | +30% |
| 2026 YTD | $8.09 | $10.9 | +35% |
FENC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.